# Sabirnetug PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sabirnetug

> The next catalyst for sabirnetug, sponsored by Acumen Pharmaceuticals, Inc. (ABOS), is its topline data readout, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for sabirnetug?

The next catalyst for sabirnetug, sponsored by Acumen Pharmaceuticals, Inc. (ABOS), is its topline data readout, early 2027. Press release filed with the SEC (EX-99): "Forward-looking statements include statements concerning Acumen's business, and Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, the potential for additional development to support a subcutaneous dosing option of sabirnetug, and the potential to develop a candidate to treat Alzheimer's Disease utilizing EBD technology." [Calendar and source filings](https://sec-api.dev/pdufa/sabirnetug)

Source: Press release filed with the SEC (EX-99), accession 0001576885-25-000102, https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112xexx991.htm (retrieved 2026-11-12). Last confirmed 2025-11-12. Cite: https://sec-api.dev/pdufa/sabirnetug#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | sabirnetug |
| Codes | ACU193 |
| Sponsor | Acumen Pharmaceuticals, Inc. (ABOS) https://sec-api.dev/companies/abos/catalysts |
| Indications | early alzheimer's disease, in late 2026, alzheimer's disease utilizing ebd technology, early ad, early alzheimer's disease, in november 2026, early ad, and today i'm pleased to announce, early ad, with topline results, [Alzheimer Disease](https://sec-api.dev/indications/alzheimer-disease) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Jul 2023: topline data readout

- Status: completed, met. Date confidence: month. Stage: 1.
- First seen 2024-11-12, last confirmed 2026-10-26.
- SEC Form 10-Q (accession 0001628280-26-067276): "In July 2023, the Company announced top-line results from its Phase 1 INTERCEPT-AD clinical trial of sabirnetug, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026067276/abos-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-056199): "In July 2023, the Company announced top-line results from its Phase 1 INTERCEPT-AD clinical trial of sabirnetug, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026056199/abos-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-034204): "In July 2023, the Company announced top-line results from its Phase 1 INTERCEPT-AD clinical trial of sabirnetug, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026034204/abos-20260331.htm
- SEC Form 10-K (accession 0001628280-26-021413): "In July 2023, the Company announced topline results from its Phase 1 INTERCEPT-AD clinical trial of sabirnetug, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/abos-20251231.htm
- SEC Form 10-Q (accession 0001576885-25-000093): "In July 2023, we announced topline results from our Phase 1 clinical trial of sabirnetug, called INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000093/abos-20250630.htm
- SEC Form 10-Q (accession 0001576885-25-000065): "In July 2023, we announced topline results from our Phase 1 clinical trial of sabirnetug, called INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000065/abos-20250331.htm
- SEC Form 10-K (accession 0001576885-25-000049): "In July 2023, we announced topline results from our Phase 1 clinical trial of sabirnetug, called INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000049/abos-20241231.htm
- SEC Form 10-Q (accession 0001628280-26-067276): "In July 2023, we announced top-line results from INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026067276/abos-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-056199): "In July 2023, we announced top-line results from INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026056199/abos-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-034204): "In July 2023, we announced top-line results from INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026034204/abos-20260331.htm
- SEC Form 10-K (accession 0001628280-26-021413): "We announced INTERCEPT-AD topline data in July of 2023, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/abos-20251231.htm
- SEC Form 10-K (accession 0001628280-26-021413): "In July 2023, we announced topline results from INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/abos-20251231.htm

### May 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-27, last confirmed 2026-03-26.
- SEC Form 10-K (accession 0001628280-26-021413): "We initiated our Phase 2 clinical trial, ALTITUDE-AD, in May 2024, completed enrollment in March 2025 and expect to announce top-line results in late 2026." https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/abos-20251231.htm
- SEC Form 10-K (accession 0001576885-25-000049): "We initiated ALTITUDE-AD, our Phase 2 clinical trial, in May 2024 and completed enrollment in March 2025." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000049/abos-20241231.htm
- SEC Form 10-K (accession 0001576885-25-000049): "We initiated our Phase 2 clinical trial, ALTITUDE-AD, in May 2024 and completed enrollment in March 2025." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000049/abos-20241231.htm

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001576885-24-000096): "•Expect to announce topline results of Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025" https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001576885-24-000096): ""Additionally, we anticipate topline results from our Phase 1 healthy volunteer study investigating subcutaneous sabirnetug in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001576885-24-000096): "•The Company expects to announce topline results of a Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001576885-24-000096): "Population: Ongoing Phase 1 Subcutaneous Healthy Volunteer Study Topline Results Expected in Q1 2025 Output: IV dose (1/month) (n = 12)" https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/acumen_ncxcorporatexdeck.htm
- SEC Form 10-Q (accession 0001576885-24-000098): "Topline results from this study are expected in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1576885/000157688524000098/abos-20240930.htm

### Nov 2025: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: early Alzheimer's disease.
- First seen 2026-03-26, last confirmed 2026-03-26.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-021189): "•In November 2025, the Company dosed the first patient in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in patients with early Alzheimer's disease." https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/abos-20260326xexx991.htm

### October 29, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Alzheimer Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Acumen Pharmaceuticals." https://clinicaltrials.gov/study/NCT06335173

### Nov 2026: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2. Indication: early Alzheimer's disease, in late 2026.
- First seen 2025-03-27, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-067129): "Topline results expected in November 2026 Key Highlights" https://www.sec.gov/Archives/edgar/data/1576885/000162828026067129/acumen_ncxcorporatexdeck.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-055940): "Topline results expected in late 2026 Key Highlights" https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/acumen_ncxcorporatexdeck.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-033868): "Topline results expected in late 2026 Key Highlights" https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/acumen_ncxcorporatexdeck.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-021189): "Topline results expected in late 2026 Key Highlights" https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/acumen_ncxcorporatexdeck.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-017885): "Topline results expected in late 2026 Key Highlights" https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/acumen_ncxcorporatexdeck.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-001774): "Topline results expected in late 2026 Key Highlights" https://www.sec.gov/Archives/edgar/data/1576885/000162828026001774/acumen_ncxcorporatexdeck.htm
- Press release filed with the SEC (EX-99) (accession 0001576885-25-000044): "◦Anticipate topline results in late 2026" https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/abos-20250327xexx991.htm
- SEC Form 10-Q (accession 0001628280-26-067276): "We plan to announce top-line results in November 2026." https://www.sec.gov/Archives/edgar/data/1576885/000162828026067276/abos-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-056199): "We plan to announce top-line results in late 2026." https://www.sec.gov/Archives/edgar/data/1576885/000162828026056199/abos-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-034204): "We plan to announce top-line results in late 2026." https://www.sec.gov/Archives/edgar/data/1576885/000162828026034204/abos-20260331.htm
- SEC prospectus (424B) (accession 0001628280-25-051852): "We completed enrollment in March 2025 and expect to announce top-line results for ALTITUDE-AD in late 2026." https://www.sec.gov/Archives/edgar/data/1576885/000162828025051852/acumen-424b5.htm
- ClinicalTrials.gov: "NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Acumen Pharmaceuticals." https://clinicaltrials.gov/study/NCT06335173

### early 2027: topline data readout

- Status: scheduled. Date confidence: half. Indication: Alzheimer's Disease utilizing EBD technology.
- First seen 2025-03-27, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001576885-25-000102): "Forward-looking statements include statements concerning Acumen's business, and Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, the potential for additional development to support a subcutaneous dosing option of sabirnetug, and the potential to develop a candidate to treat Alzheimer's Disease utilizing EBD technology." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001576885-25-000091): "Forward-looking statements include statements concerning Acumen's business, and Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, the potential for additional development to support a subcutaneous dosing option of sabirnetug, and the potential to develop a candidate to treat Alzheimer's Disease utilizing EBD technology." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/abos-20250812xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001576885-25-000062): "3 its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, and the potential for additional development to support a subcutaneous dosing option of sabirnetug." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000062/abos-20250513xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001576885-25-000044): "Forward-looking statements include statements concerning Acumen's business, and Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into the first half of 2027, the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, and the potential for additional development to support a subcutaneous dosing option of sabirnetug." https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/abos-20250327xexx991.htm

## Same indication

- [[18f]pi-2620](https://sec-api.dev/pdufa/18f-pi-2620) (LNTH)
- [Dn-tnf](https://sec-api.dev/pdufa/dn-tnf) (INMB)
- [Donanemab](https://sec-api.dev/pdufa/donanemab) (LLY)
- [Igc-ad1-active](https://sec-api.dev/pdufa/igc-ad1-active) (IGC)
- [JNJ-63733657](https://sec-api.dev/pdufa/jnj-63733657) (JNJ)
- [JNJ-64042056](https://sec-api.dev/pdufa/jnj-64042056) (JNJ)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [Mevidalen](https://sec-api.dev/pdufa/mevidalen) (LLY)
- [MK-1167](https://sec-api.dev/pdufa/mk-1167) (MRK)
- [PMN310](https://sec-api.dev/pdufa/pmn310) (PMN)
- [Primec](https://sec-api.dev/pdufa/primec) (NRSN)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sabirnetug.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sabirnetug PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sabirnetug

```bibtex
@misc{secapidev_pdufa_sabirnetug_20261116,
  title        = {Sabirnetug PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sabirnetug}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sabirnetug_20261116","title":"Sabirnetug PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sabirnetug","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
